查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594677

光學疾病治療市場：按處方類型、治療方法和最終用戶分類 - 全球預測 2025-2030

Optical Disorders Drugs Market by Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs), Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，光學疾病治療市場估值為31.4億美元，預計到2024年將達到35.6億美元，複合年成長率為13.29%，預計到2030年將達到75.4億美元。

光學疾病治療市場的範圍包括旨在治療各種眼科疾病的藥物，例如青光眼、黃斑部病變、糖尿病視網膜病變和白內障。這些藥物通常透過降低眼壓、減緩疾病進展和預防感染來發揮作用，對於維持眼睛健康和視力至關重要。由於人口老化以及糖尿病和其他影響視力的健康狀況的增加，眼部疾病的盛行率不斷增加，證明了對此類藥物的需求。這些治療方法適用於醫院、診所和居家醫療機構，並具有廣泛的最終用途。

主要市場統計
基準年[2023] 31.4億美元
預測年份 [2024] 35.6億美元
預測年份 [2030] 75.4億美元
複合年成長率（%） 13.29%

市場成長受到配方和給藥方法技術進步、醫療保健支出增加（尤其是在新興經濟體）以及預防性眼部保健意識提高的顯著影響。基因治療、個人化醫療以及緩釋性植入等新型藥物輸送系統的開發等領域的技術創新提供了充滿希望的機會。值得注意的是，生物技術公司和研究機構之間的研究合作和夥伴關係正在推動市場發展。

然而，市場面臨一些挑戰，包括研發成本上升導致治療費用昂貴、監管障礙減緩了醫藥品認證過程以及低度開發地區的准入有限。此外，競爭格局非常激烈，許多公司都在爭奪市場佔有率，這可能會導致高昂的定價壓力。

為了利用市場機會，公司應該專注於有潛力在治療功效和患者結果方面帶來突破的研究領域，例如再生醫學和生技藥品。也建議投資數位健康解決方案和遠距眼科，以有效進入服務不足的市場。市場的本質是動態的，受到快速的技術進步和不斷變化的患者需求的驅動，需要持續創新和策略適應性來保持成長和相關性。

市場動態：快速發展的光學疾病治療市場的關鍵市場洞察

供需的動態交互作用正在改變光學疾病治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 由於數位化接觸增加和不健康的生活方式導致需求增加
    • 老年人口眼相關疾病的盛行率
    • 隱形眼鏡使用增加和相關疾病
  • 市場限制因素
    • 新興經濟體治療費用高且缺乏醫療保險
  • 市場機會
    • 光學化學技術進步
    • 青光眼盛行率上升和醫療支出增加
  • 市場挑戰
    • 藥物對健康的不良影響

波特五力：駕馭視科疾病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對眼科疾病藥物市場的影響

外部宏觀環境因素在塑造視神經疾病治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解眼科疾病治療藥物市場的競爭狀況

對光學疾病治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣光學疾病治療市場供應商的績效評估

FPNV定位矩陣是評估光學疾病治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，以規劃光學疾病治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對光學疾病治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於數位化接觸增加和不健康的生活方式導致需求增加
      • 老年人眼相關疾病的盛行率
      • 隱形眼鏡使用率和相關疾病的增加
    • 抑制因素
      • 新興經濟體的治療費用高且缺乏健康保險
    • 機會
      • 視力矯正藥物的技術進步
      • 青光眼發生率上升和醫療費用上升
    • 任務
      • 藥物對健康的不良影響
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依處方箋的眼科疾病治療藥物市場

  • 非處方藥
  • 處方眼藥

第7章 光學疾病治療藥物市場治療

  • 老齡化黃斑部病變
  • 結膜炎
  • 糖尿病黃斑部水腫
  • 糖尿病視網膜病變
  • 乾眼症
  • 眼癌
  • 地圖狀萎縮
  • 青光眼
  • 角膜炎
  • 晶狀體混濁和人工水晶體
  • 視網膜靜脈阻塞

第8章光學疾病治療市場：依最終使用者分類

  • 診斷中心
  • 眼科診所
  • 醫院
  • 病人

第9章 北美、南美光學疾病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太視光疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲/中東/非洲眼科疾病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Cipla Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Kiora Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Nicox SA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals Inc
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-434CCDA05224

The Optical Disorders Drugs Market was valued at USD 3.14 billion in 2023, expected to reach USD 3.56 billion in 2024, and is projected to grow at a CAGR of 13.29%, to USD 7.54 billion by 2030.

The scope of the optical disorders drugs market encompasses medications intended to treat various eye conditions, such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts. These drugs are critical for maintaining eye health and vision, often acting by reducing intraocular pressure, slowing disease progression, or preventing infection. The necessity for such medications is underscored by the growing prevalence of optical disorders due to aging populations and increasing incidences of diabetes and other health conditions that can affect vision. These treatments find application in hospitals, clinics, and home care settings, ensuring a broad end-use scope.

KEY MARKET STATISTICS
Base Year [2023] USD 3.14 billion
Estimated Year [2024] USD 3.56 billion
Forecast Year [2030] USD 7.54 billion
CAGR (%) 13.29%

Market growth is significantly influenced by technological advancements in drug formulations and delivery methods, increased healthcare spending, particularly in emerging economies, and rising awareness of preventative eye care. Innovation in areas such as gene therapy, personalized medicine, and the development of novel drug delivery systems like sustained-release implants present promising opportunities. Notably, collaborations and partnerships among biotech firms and research institutions can drive market advancement.

However, the market confronts several challenges, including high R&D costs leading to expensive treatments, regulatory hurdles that can delay drug approval processes, and limited accessibility in underdeveloped regions. Furthermore, the competitive landscape is intense, with numerous players striving for a share of the market, potentially leading to high pricing pressure.

To capitalize on market opportunities, companies should focus on research areas such as regenerative medicine and biologics, which hold the potential for breakthroughs in treatment efficacy and patient outcomes. Firms are also encouraged to invest in digital health solutions and teleophthalmology to reach underserved markets effectively. The nature of the market remains dynamic, driven by rapid technological advancements and evolving patient needs, requiring continuous innovation and strategic adaptability to sustain growth and relevance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Optical Disorders Drugs Market

The Optical Disorders Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising demand owing to increased digital exposure and unhealthy lifestyle
    • Prevalence of eye related disorders in geriatric population
    • Rise in the use of contact lenses and related disorders
  • Market Restraints
    • High treatment cost and lack of health insurance in developing economies
  • Market Opportunities
    • Technological advancements in optic drugs
    • Rising prevalence of glaucoma and an increase in healthcare expenditure
  • Market Challenges
    • Adverse health impacts of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Optical Disorders Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Optical Disorders Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Optical Disorders Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Optical Disorders Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Optical Disorders Drugs Market

A detailed market share analysis in the Optical Disorders Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Optical Disorders Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Optical Disorders Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Optical Disorders Drugs Market

A strategic analysis of the Optical Disorders Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Optical Disorders Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch & Lomb Incorporated, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Kiora Pharmaceuticals, Inc., Merck & Co., Inc., Nicox SA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Optical Disorders Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Prescription Type, market is studied across Over-The-Counter Drugs and Prescription Ophthalmic Drugs.
  • Based on Therapeutics, market is studied across Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Geographic Atrophy, Glaucoma, Keratitis, Lens Opacification & Intraocular Lens, and Retinal Vein Occlusion.
  • Based on End-User, market is studied across Diagnostic Centers, Eye Clinics, Hospitals, and Patient.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising demand owing to increased digital exposure and unhealthy lifestyle
      • 5.1.1.2. Prevalence of eye related disorders in geriatric population
      • 5.1.1.3. Rise in the use of contact lenses and related disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment cost and lack of health insurance in developing economies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in optic drugs
      • 5.1.3.2. Rising prevalence of glaucoma and an increase in healthcare expenditure
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse health impacts of drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Optical Disorders Drugs Market, by Prescription Type

  • 6.1. Introduction
  • 6.2. Over-The-Counter Drugs
  • 6.3. Prescription Ophthalmic Drugs

7. Optical Disorders Drugs Market, by Therapeutics

  • 7.1. Introduction
  • 7.2. Age-Related Macular Degeneration
  • 7.3. Conjunctivitis
  • 7.4. Diabetic Macular Edema
  • 7.5. Diabetic Retinopathy
  • 7.6. Dry Eye
  • 7.7. Eye Cancer
  • 7.8. Geographic Atrophy
  • 7.9. Glaucoma
  • 7.10. Keratitis
  • 7.11. Lens Opacification & Intraocular Lens
  • 7.12. Retinal Vein Occlusion

8. Optical Disorders Drugs Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Eye Clinics
  • 8.4. Hospitals
  • 8.5. Patient

9. Americas Optical Disorders Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Optical Disorders Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Optical Disorders Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bausch & Lomb Incorporated
  • 3. Bayer AG
  • 4. Cipla Limited
  • 5. F. Hoffmann-La Roche Ltd
  • 6. GlaxoSmithKline PLC
  • 7. Kiora Pharmaceuticals, Inc.
  • 8. Merck & Co., Inc.
  • 9. Nicox SA
  • 10. Novartis AG
  • 11. Pfizer, Inc.
  • 12. Regeneron Pharmaceuticals Inc
  • 13. Santen Pharmaceutical Co., Ltd.
  • 14. Senju Pharmaceutical Co., Ltd.
  • 15. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. OPTICAL DISORDERS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OPTICAL DISORDERS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OPTICAL DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OPTICAL DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OPTICAL DISORDERS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OPTICAL DISORDERS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION & INTRAOCULAR LENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 65. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 68. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 71. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 74. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 77. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 80. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 83. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 93. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 96. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 99. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 105. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 111. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 114. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 117. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 120. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 126. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 129. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 132. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 141. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 144. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 147. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. OPTICAL DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 155. OPTICAL DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023